Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DMACNASDAQ:ENOBNASDAQ:LYELNASDAQ:RAPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDMACDiaMedica Therapeutics$3.95+5.9%$3.98$2.49▼$6.82$159.96M1.2389,635 shs211,101 shsENOBEnochian Biosciences$0.61$0.39▼$2.99$40.80M1.09137,347 shs88,300 shsLYELLyell Immunopharma$9.29-3.1%$9.12$7.65▼$38.40$141.93M-0.2670,110 shs101,670 shsRAPTRapt Therapeutics$9.56+16.3%$7.55$5.67▼$30.60$135.93M-0.11162,439 shs168,474 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDMACDiaMedica Therapeutics+5.90%+3.40%-2.71%-4.59%+74.78%ENOBEnochian Biosciences0.00%0.00%0.00%0.00%0.00%LYELLyell Immunopharma-3.13%-3.03%+11.10%-21.75%-77.23%RAPTRapt Therapeutics+16.30%+28.84%-2.85%-15.55%-61.20%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDMACDiaMedica Therapeutics1.178 of 5 stars3.51.00.00.01.50.00.0ENOBEnochian BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ALYELLyell Immunopharma3.5056 of 5 stars2.83.00.00.03.05.01.3RAPTRapt Therapeutics3.8289 of 5 stars3.21.00.04.21.91.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDMACDiaMedica Therapeutics 3.00Buy$8.00102.53% UpsideENOBEnochian Biosciences 0.00N/AN/AN/ALYELLyell Immunopharma 1.50Reduce$15.0061.46% UpsideRAPTRapt Therapeutics 2.33Hold$24.00151.05% UpsideCurrent Analyst Ratings BreakdownLatest ENOB, DMAC, RAPT, and LYEL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2025LYELLyell ImmunopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$10.005/29/2025DMACDiaMedica TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.005/22/2025RAPTRapt TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$16.00 ➝ $8.005/22/2025RAPTRapt TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$48.004/16/2025LYELLyell ImmunopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$20.00 ➝ $20.00(Data available from 6/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDMACDiaMedica TherapeuticsN/AN/AN/AN/A$0.95 per shareN/AENOBEnochian BiosciencesN/AN/AN/AN/A$1.37 per shareN/ALYELLyell Immunopharma$60K2,293.08N/AN/A$26.21 per share0.35RAPTRapt Therapeutics$1.53M103.35N/AN/A$11.51 per share0.83Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDMACDiaMedica Therapeutics-$24.44M-$0.64N/AN/AN/AN/A-61.35%-55.53%8/6/2025 (Estimated)ENOBEnochian Biosciences-$113.43MN/A0.00N/AN/AN/A-154.69%-130.66%N/ALYELLyell Immunopharma-$342.99M-$25.00N/AN/AN/A-514,649.22%-73.66%-60.99%8/6/2025 (Estimated)RAPTRapt Therapeutics-$129.87M-$19.20N/AN/AN/AN/A-81.47%-70.24%8/6/2025 (Estimated)Latest ENOB, DMAC, RAPT, and LYEL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025DMACDiaMedica Therapeutics-$0.18-$0.18N/A-$0.18N/AN/A5/13/2025Q1 2025LYELLyell Immunopharma-$3.80-$3.60+$0.20-$0.18N/A$0.01 million5/8/2025Q1 2025RAPTRapt Therapeutics-$2.48-$0.64+$1.84-$0.08N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDMACDiaMedica TherapeuticsN/AN/AN/AN/AN/AENOBEnochian BiosciencesN/AN/AN/AN/AN/ALYELLyell ImmunopharmaN/AN/AN/AN/AN/ARAPTRapt TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDMACDiaMedica TherapeuticsN/A8.028.02ENOBEnochian BiosciencesN/A0.330.33LYELLyell ImmunopharmaN/A7.497.49RAPTRapt TherapeuticsN/A21.1121.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDMACDiaMedica Therapeutics10.12%ENOBEnochian Biosciences7.16%LYELLyell Immunopharma66.05%RAPTRapt Therapeutics99.09%Insider OwnershipCompanyInsider OwnershipDMACDiaMedica Therapeutics7.30%ENOBEnochian Biosciences21.72%LYELLyell Immunopharma22.30%RAPTRapt Therapeutics2.36%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDMACDiaMedica Therapeutics2042.88 million39.75 millionOptionableENOBEnochian Biosciences2258.28 million45.63 millionNot OptionableLYELLyell Immunopharma27014.81 million11.51 millionOptionableRAPTRapt Therapeutics8016.54 million16.15 millionOptionableENOB, DMAC, RAPT, and LYEL HeadlinesRecent News About These CompaniesRAPT Therapeutics expands board with two new directorsJune 25 at 1:54 PM | investing.comRAPT Therapeutics Appoints Scott Braunstein, M.D. and Ashley Dombkowski, Ph.D. to Board of Directors - NasdaqJune 25 at 1:54 PM | nasdaq.comRAPT Therapeutics Names Two Industry Veterans to its Board of DirectorsJune 23 at 8:00 AM | globenewswire.comRapt Therapeutics (NASDAQ:RAPT) Downgraded by Wall Street Zen to SellJune 22, 2025 | americanbankingnews.comRapt Therapeutics (NASDAQ:RAPT) Lowered to Sell Rating by Wall Street ZenJune 21, 2025 | marketbeat.comRapt Therapeutics (NASDAQ:RAPT) Shares Gap Down - Time to Sell?June 18, 2025 | marketbeat.comWall Street Analysts Predict a 282.65% Upside in Rapt Therapeutics (RAPT): Here's What You Should KnowJune 18, 2025 | zacks.comRAPT Finalizes Reverse Split Plan; 1-for-8 Ratio Effective June 16, 2025June 15, 2025 | nasdaq.comRAPT Therapeutics, Inc. Announces 1-for-8 Reverse Stock Split Effective June 16, 2025June 15, 2025 | nasdaq.comRAPT Therapeutics (NASDAQ:RAPT) Shares Scheduled to Reverse Split on Tuesday, June 17thJune 13, 2025 | marketbeat.comRAPT Therapeutics, Inc.: RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock SplitJune 13, 2025 | finanznachrichten.deRAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock SplitJune 13, 2025 | globenewswire.comTwo Sigma Investments LP Sells 339,957 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT)June 12, 2025 | marketbeat.comClear Street initiates Rapt Therapeutics stock with buy ratingJune 7, 2025 | uk.investing.comRapt Therapeutics Get A Bullish Recommendation On ‘Significant Opportunity’ For Allergy Drug Candidate: Retail Worries About Cash PositionJune 6, 2025 | msn.comRapt Therapeutics cuts staff for 2nd time in under a year, continuing fallout from FDA holdJune 4, 2025 | fiercebiotech.comFRAPT Therapeutics to Participate in Upcoming Investor ConferencesJune 4, 2025 | globenewswire.comRAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Consensus Recommendation of "Hold" from BrokeragesJune 3, 2025 | marketbeat.comShort Interest in RAPT Therapeutics, Inc. (NASDAQ:RAPT) Rises By 39.9%June 2, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for RAPT Q2 Earnings?May 27, 2025 | marketbeat.com12 Health Care Stocks Moving In Friday's Intraday SessionMay 25, 2025 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeENOB, DMAC, RAPT, and LYEL Company DescriptionsDiaMedica Therapeutics NASDAQ:DMAC$3.95 +0.22 (+5.90%) Closing price 06/25/2025 04:00 PM EasternExtended Trading$3.92 -0.03 (-0.63%) As of 06/25/2025 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Enochian Biosciences NASDAQ:ENOBEnochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer. The company's product pipeline includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a gene therapy curative treatment for HBV. It develops ENOB-DC-11, an allogeneic dendritic cell therapeutic vaccine for solid tumors; ENOB-DC-12-XX, allogeneic dendritic cell therapeutic vaccine for other solid tumors; and ENOB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. Enochian Biosciences, Inc. has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was incorporated in 2017 and is headquartered in Los Angeles, California.Lyell Immunopharma NASDAQ:LYEL$9.29 -0.30 (-3.13%) Closing price 06/25/2025 04:00 PM EasternExtended Trading$9.15 -0.14 (-1.51%) As of 06/25/2025 06:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.Rapt Therapeutics NASDAQ:RAPT$9.56 +1.34 (+16.30%) Closing price 06/25/2025 04:00 PM EasternExtended Trading$8.82 -0.74 (-7.74%) As of 06/25/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside AeroVironment Will Hit New Highs This Year: Bull Flag Confirmed Uber and Tesla Surge on Robotaxis, Analyst Touts Texas Rides Palantir Stock Hits ATH, But Can the Rally Hold Without Volume? Costco at a Crossroads: Is the Next Move Higher or Lower? AST SpaceMobile's Signal Strengthens as Stock Nears Orbit Oracle Stock Boils Higher, $300 Price Target in Sight 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
